Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

Ratios

vs
industry
vs
history
P/E(ttm) 17.77
PID's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 17.77 )
Ranked among companies with meaningful P/E(ttm) only.
PID' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 18.04
Current: 17.77
0
18.04
PE(NRI) 17.77
PID's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 17.77 )
Ranked among companies with meaningful PE(NRI) only.
PID' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 18.04
Current: 17.77
0
18.04
P/B 1.51
PID's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 1.51 )
Ranked among companies with meaningful P/B only.
PID' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.6
Current: 1.51
0
1.6

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.92
PID's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 3.92 )
Ranked among companies with meaningful Dividend Yield only.
PID' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.05
Current: 3.92
0
4.05
Yield on cost (5-Year) 3.92
PID's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PID: 3.92 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PID' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.05
Current: 3.92
0
4.05

More Statistics

Short Percentage of Float0.00%
52-Week Range $11.44 - 15.65
Shares Outstanding (Mil)47,300,000.00
» More Articles for PID

Headlines

Articles On GuruFocus.com
Semiconductor Industry Offers High Growth Potential Sep 28 2016 
Australian Scentre Pays 4.4% Dividend Sep 28 2016 
Primo Water Reports 210% Increase in Net Income Sep 28 2016 
American Financial CEO Sells Shares in Company Sep 28 2016 
Legendary Value Investor Jean-Marie Eveillard Will Speak at 2017 GuruFocus Value Conference, Omaha Sep 28 2016 
Ariel Funds Comments on Harman Intl Industries Inc. Sep 28 2016 
Ariel Funds Comments on Baidu Inc. Sep 28 2016 
Ariel Funds Comments on GlaxoSmithKline plc Sep 28 2016 
Ariel Funds Comments on Johnson & Johnson Sep 28 2016 
Qualcomm Holding On in the Face of Adversity Sep 28 2016 

More From Other Websites
Teva’s Share of the US Generics Market Could Boost Its Stock Sep 28 2016
Winning? We Review How Teva Dominates Generic Drug Space Sep 26 2016
Sanofi’s Chase for Zika Virus Vaccine Could Drive Its Share Price Sep 15 2016
Will Sanofi See More Growth from Its Blockbuster Insulin Drug? Sep 15 2016
GSK Optimistic about Future of Its Consumer Healthcare Segment Sep 13 2016
GlaxoSmithKline Giving a Shot to Its Vaccines Business Sep 13 2016
GlaxoSmithKline’s Combo Treatment for HIV Faces Stiff Competition Sep 12 2016
5 Undervalued ETFs for Dividend Lovers Sep 08 2016
Analyzing Sanofi’s Asset Swap Deal with Boehringer Ingelheim Sep 08 2016
Teva Pharmaceutical: A Successful Bond Financing Program in 2016 Aug 22 2016
How Merial Contributes to Sanofi’s Growth Aug 22 2016
What Happened to Sanofi’s Consumer Healthcare and Generics Franchise in 2Q16? Aug 19 2016
Behind Sanofi’s Diabetes and Cardiovascular Performance in 2Q16 Aug 18 2016
Genzyme Continued to Boost Growth for Sanofi in 2Q16 Aug 18 2016
Inside Sanofi’s Valuation Changes Aug 17 2016
How Did Novo Nordisk Perform across Geographies in 1H16? Aug 09 2016
A New Low Volatile International ETF for Dividend Lovers Aug 08 2016
A New Low Volatility International ETF for Dividend Lovers Aug 08 2016
An Update on Shire’s Upcoming Milestones Aug 05 2016
How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 2Q16? Aug 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK